Joaquim Bellmunt, MD, PhD, on Bladder Cancer: The Future of Immunotherapies

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, discusses refining treatment choices with new combinations and sequencing strategies.

Advertisement

Advertisement



Aug
17
Today In Oncology
FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma
Issues in Doctor-Patient Discussions on Potential Harms of Lung Cancer Screening
VB4-845 Granted Fast Track Designation by FDA for Treatment of Non–Muscle Invasive Bladder Cancer
Basal Cell Carcinoma and Risk for Development of Other Cancers
Broad-Based Genomic Sequencing in Advanced NSCLC in the Community Oncology Setting
View More 
;
Advertisement
© 2018 HSP News Service, L.L.C.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.